Drug intelligence / Profile preview

ZK2601

Development stage: Preclinical
Lead developer: Lee's Pharmaceutical
Administration: Oral

Overview

ZK2601 is an early-stage therapeutic candidate being developed by Lee's Pharmaceutical for the treatment of solid tumors. Currently in the preclinical phase, the drug is part of Lee's Pharmaceutical's internal oncology pipeline, where it is often listed alongside other early-stage assets such as ZK2501. As of current public disclosures, specific details regarding its molecular target, mechanism of action, and chemical modality (e.g., small molecule or biologic) have not been revealed by the sponsor.

Beyond the preview

Go deeper on ZK2601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK2601.

Explore the full profile